OTC · CIK 0001815974
ANEB Anebulo Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Apr 7, 2025. Close $0.31 on Oct 9, 2026, +31400% from the 52-week low and -89% from the high.
Anebulo Pharmaceuticals, Inc. (ANEB) has 11 SEC Form 4 filings on file from 9 insiders, the latest filed on Apr 7, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at ANEB. The newest: Aron R. English (director and 10% owner) bought $10.0M of stock on Dec 23, 2024, filed Dec 26, 2024, scored 50 (moderate).
ANEB closed at $0.31 on Oct 9, 2026, 31400% above its 52-week low and 89% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Anebulo Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Aron R. English director, owner buy | $10.0M 10,101,010 shares | +188% | - |
Transactions
Every row filed, 18 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 4, 2025 | Areta Kupchyk director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 7, 2025 |
| Apr 4, 2025 | Aron R. English director, owner | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 7, 2025 |
| Apr 4, 2025 | Richard Anthony Cunningham Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +316,352 | $0.00 | $0 | 316,352 | Apr 7, 2025 |
| Apr 4, 2025 | Bimal R. Shah director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 7, 2025 |
| Apr 4, 2025 | Kenneth C Cundy Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +115,037 | $0.00 | $0 | 115,037 | Apr 7, 2025 |
| Apr 4, 2025 | Kenneth Lin director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 7, 2025 |
| Apr 4, 2025 | Nathaniel Calloway director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 7, 2025 |
| Apr 4, 2025 | Jason Aryeh director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 7, 2025 |
| Apr 4, 2025 | Joseph F. Lawler director, owner | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Apr 7, 2025 |
| Apr 4, 2025 | Areta Kupchyk director | AGrant or award Stock Option (right to buy)derivative | +2,647 | $0.00 | $0 | 2,647 | Apr 7, 2025 |
| Apr 4, 2025 | Nathaniel Calloway director | AGrant or award Stock Option (right to buy)derivative | +3,309 | $0.00 | $0 | 3,309 | Apr 7, 2025 |
| Apr 4, 2025 | Joseph F. Lawler director, owner | AGrant or award Stock Option (right to buy)derivative | +13,236 | $0.00 | $0 | 13,236 | Apr 7, 2025 |
| Apr 4, 2025 | Jason Aryeh director | AGrant or award Stock Option (right to buy)derivative | +4,964 | $0.00 | $0 | 4,964 | Apr 7, 2025 |
| Apr 4, 2025 | Kenneth Lin director | AGrant or award Stock Option (right to buy)derivative | +4,964 | $0.00 | $0 | 4,964 | Apr 7, 2025 |
| Apr 4, 2025 | Bimal R. Shah director | AGrant or award Stock Option (right to buy)derivative | +6,618 | $0.00 | $0 | 6,618 | Apr 7, 2025 |
| Apr 4, 2025 | Aron R. English director, owner | AGrant or award Stock Option (right to buy)derivative | +2,647 | $0.00 | $0 | 2,647 | Apr 7, 2025 |
| Dec 23, 2024 | Aron R. English director, owner | POpen-market purchase Common Stockindirect: 22NW Fund, LP | +10,101,010 | $0.99 | $10.0M | 15,467,300 | Dec 26, 2024 |
| Dec 9, 2024 | Richard Anthony Cunningham Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +254,433 | $0.00 | $0 | 254,433 | Dec 10, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jason Aryehdirector
- Nathaniel Callowaydirector
- Kenneth C CundyChief Scientific Officer
- Richard Anthony CunninghamChief Executive Officer
- Aron R. Englishowner, director
- Areta Kupchykdirector
- Joseph F. Lawlerdirector, owner
- Kenneth Lindirector
- Bimal R. Shahdirector
Questions about ANEB
Answered from the filings on this page, as of the latest one.
Are insiders buying ANEB?
No. In the last 90 days no insider at Anebulo Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ANEB on the open market?
Aron R. English (director and 10% owner) bought $10.0M of ANEB on Dec 23, 2024 and filed the Form 4 on Dec 26, 2024. InsiderTell scored 50 (moderate).
How many insiders file Form 4 at Anebulo Pharmaceuticals, Inc.?
9 people have filed a Form 4 at Anebulo Pharmaceuticals, Inc., among them Jason Aryeh (director), Nathaniel Calloway (director), Kenneth C Cundy (Chief Scientific Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.